Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients

[1]  J. Santibañez,et al.  How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions , 2019, Cancer Immunology, Immunotherapy.

[2]  R. Bonecchi,et al.  Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy , 2019, Front. Immunol..

[3]  B. Han,et al.  Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy , 2019, European Respiratory Journal.

[4]  J. Pollard,et al.  Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates , 2019, Cancer Immunology, Immunotherapy.

[5]  Yadan Wang,et al.  Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis , 2018, BMC Cancer.

[6]  T. Kuijpers,et al.  Neutrophils as myeloid‐derived suppressor cells , 2018, European journal of clinical investigation.

[7]  J. Kamińska,et al.  Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients , 2018, Irish Journal of Medical Science (1971 -).

[8]  A. Przylipiak,et al.  Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients , 2018, BioMed research international.

[9]  M. Bobiński,et al.  Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells – is a new era coming? , 2018, Critical reviews in clinical laboratory sciences.

[10]  J. Takala,et al.  Global Asbestos Disaster , 2018, International journal of environmental research and public health.

[11]  J. Aerts,et al.  Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma , 2018, International journal of molecular sciences.

[12]  M. Ernst,et al.  Targeting Macrophages in Cancer: From Bench to Bedside , 2018, Front. Oncol..

[13]  J. Utikal,et al.  Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression , 2018, Front. Immunol..

[14]  S. Singhal,et al.  Human neutrophils can mimic myeloid-derived suppressor cells (PMN-MDSC) and suppress microbead or lectin-induced T cell proliferation through artefactual mechanisms , 2018, Scientific Reports.

[15]  Geert Raes,et al.  Beyond the M‐CSF receptor – novel therapeutic targets in tumor‐associated macrophages , 2018, The FEBS journal.

[16]  C. Ries,et al.  A drug development perspective on targeting tumor‐associated myeloid cells , 2018, The FEBS journal.

[17]  P. Murray.  Nonresolving macrophage‐mediated inflammation in malignancy , 2018, The FEBS journal.

[18]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.

[19]  E. Jensen,et al.  Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation , 2017, Nature Medicine.

[20]  W. Gillanders,et al.  Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma , 2017, Gut.

[21]  J. Aerts,et al.  Novel insights into mesothelioma biology and implications for therapy , 2017, Nature Reviews Cancer.

[22]  P. Sinha,et al.  Frontline Science: Myeloid‐derived suppressor cells (MDSCs) facilitate maternal–fetal tolerance in mice , 2017, Journal of leukocyte biology.

[23]  A. Wang-Gillam,et al.  Promising therapeutics of gastrointestinal cancers in clinical trials. , 2017, Journal of gastrointestinal oncology.

[24]  K. Sheahan,et al.  Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity , 2017, Front. Immunol..

[25]  C. Poets,et al.  HLA‐G promotes myeloid‐derived suppressor cell accumulation and suppressive activity during human pregnancy through engagement of the receptor ILT4 , 2017, European journal of immunology.

[26]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[27]  M. Wang,et al.  Combination of IL-6, IL-10, and MCP-1 with traditional serum tumor markers in lung cancer diagnosis and prognosis. , 2016, Genetics and molecular research : GMR.

[28]  Li Liu,et al.  The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis , 2016, PloS one.

[29]  C. Blanquart,et al.  Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  K. Leandersson,et al.  On the origin of myeloid-derived suppressor cells , 2016, Oncotarget.

[31]  M. Takeya,et al.  Role of tumor‐associated macrophages in human malignancies: friend or foe? , 2016, Pathology international.

[32]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[33]  A. Zhao,et al.  Granulocytic myeloid-derived suppressor cells maintain feto-maternal tolerance by inducing Foxp3 expression in CD4+CD25-T cells by activation of the TGF-β/β-catenin pathway. , 2016, Molecular human reproduction.

[34]  K. E. Visser,et al.  Neutrophils in cancer: neutral no more , 2016, Nature Reviews Cancer.

[35]  Kathryn J Fowler,et al.  Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. , 2016, The Lancet. Oncology.

[36]  R. Muschel,et al.  Targeting the CCL2-CCR2 signaling axis in cancer metastasis , 2016, Oncotarget.

[37]  L. Lenz,et al.  A Breakthrough: Macrophage-Directed Cancer Immunotherapy. , 2016, Cancer research.

[38]  H. Abele,et al.  Granulocytic Myeloid-Derived Suppressor Cells Accumulate in Human Placenta and Polarize toward a Th2 Phenotype , 2016, The Journal of Immunology.

[39]  G. Lesinski,et al.  Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer , 2015, Clinical Cancer Research.

[40]  S. M. Seyedmehdi,et al.  The Intricate Expression of CC Chemokines in Glial Tumors: Evidence for Involvement of CCL2 and CCL5 but Not CCL11. , 2015, Acta medica Iranica.

[41]  Zhiwei Chen,et al.  Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells , 2015, Oncotarget.

[42]  Jie Wang,et al.  Expression of CCL2 is significantly different in five breast cancer genotypes and predicts patient outcome. , 2015, International journal of clinical and experimental medicine.

[43]  D. Boraschi,et al.  New Insights Into Tissue Macrophages: From Their Origin to the Development of Memory , 2015, Immune network.

[44]  W. Garrett,et al.  CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function , 2015, Cell reports.

[45]  Brian Ruffell,et al.  Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.

[46]  T. Daemen,et al.  Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication , 2015, Oncoimmunology.

[47]  T. Daemen,et al.  Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy , 2015, Oncoimmunology.

[48]  Zhiwei Chen,et al.  Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment. , 2014, Cancer research.

[49]  G. Bartsch,et al.  CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study , 2014, Cancer research and treatment : official journal of Korean Cancer Association.

[50]  H. Hoogsteden,et al.  Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma , 2014, PloS one.

[51]  N. Itano,et al.  Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment , 2014, Cancers.

[52]  Bing Li,et al.  Serum CCL2 and CCL3 as potential biomarkers for the diagnosis of oral squamous cell carcinoma , 2014, Tumor Biology.

[53]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[54]  J. Blay,et al.  Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.

[55]  Jennifer R. Rider,et al.  Elevated IL‐8, TNF‐α, and MCP‐1 in men with metastatic prostate cancer starting androgen‐deprivation therapy (ADT) are associated with shorter time to castration‐resistance and overall survival , 2014, The Prostate.

[56]  Long-Bang Chen,et al.  Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer and its relationship with tumor hypoxia. , 2014, World journal of gastroenterology.

[57]  S. Gordon,et al.  The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.

[58]  Hau-Ren Chen,et al.  Monocyte Chemotactic Protein 1 (MCP-1) Modulates Pro-Survival Signaling to Promote Progression of Head and Neck Squamous Cell Carcinoma , 2014, PloS one.

[59]  Jennifer R. Rider,et al.  Elevated insulin‐like growth factor binding protein‐1 (IGFBP‐1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival , 2014, The Prostate.

[60]  S. Dey,et al.  CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. , 2013, Cancer cell.

[61]  S. Choo,et al.  Identification of Serum Monocyte Chemoattractant Protein-1 and Prolactin as Potential Tumor Markers in Hepatocellular Carcinoma , 2013, PLoS ONE.

[62]  J. Aerts,et al.  Tumor-associated macrophages in thoracic malignancies. , 2013, Lung cancer.

[63]  Yanong Wang,et al.  Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancer , 2013, BMC Clinical Pathology.

[64]  Yan Chen,et al.  Expression of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in non-small cell lung cancer and its significance , 2013, Cancer Immunology, Immunotherapy.

[65]  T. Shimura,et al.  Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. , 2012, Oncology reports.

[66]  A. Sica,et al.  Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs) , 2012, Cancer Microenvironment.

[67]  Zhi-ren Zhang,et al.  Macrophages in Tumor Microenvironments and the Progression of Tumors , 2012, Clinical & developmental immunology.

[68]  S. Lang,et al.  Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology , 2012, Cancer Immunology, Immunotherapy.

[69]  Alberto Mantovani,et al.  Macrophage plasticity and polarization: in vivo veritas. , 2012, The Journal of clinical investigation.

[70]  Y. Okada,et al.  Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. , 2012, The American journal of pathology.

[71]  J. Wolchok,et al.  Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. , 2011, Cancer research.

[72]  D. Sugarbaker,et al.  Circulating and tumor‐infiltrating myeloid cells predict survival in human pleural mesothelioma , 2011, Cancer.

[73]  T. Hyslop,et al.  Serum Monocyte Chemoattractant Protein-1 in Pancreatic Cancer , 2011, Journal of oncology.

[74]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[75]  A. Scherpereel,et al.  Identification of novel markers for the diagnosis of malignant pleural mesothelioma. , 2011, The American journal of pathology.

[76]  C. Qian,et al.  Serum CCL2 and serum TNF-α--two new biomarkers predict bone invasion, post-treatment distant metastasis and poor overall survival in nasopharyngeal carcinoma. , 2011, European journal of cancer.

[77]  H. Hoogsteden,et al.  COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function , 2010, BMC Cancer.

[78]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[79]  M. Loh,et al.  Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. , 2010, Journal of hepatology.

[80]  P. Allavena,et al.  Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation , 2009, Journal of leukocyte biology.

[81]  S. Amini,et al.  Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[82]  M. Miyazaki,et al.  Significance of monocyte chemoattractant protein-1 in angiogenesis and survival in colorectal liver metastases. , 2009, International journal of oncology.

[83]  J. Pollard.  Trophic macrophages in development and disease , 2009, Nature Reviews Immunology.

[84]  Qinghua Zhou,et al.  Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo. , 2009, Neoplasia.

[85]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[86]  P. Bradding,et al.  Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival , 2009, European Respiratory Journal.

[87]  A. Mantovani,et al.  From phagocyte diversity and activation to probiotics: Back to Metchnikoff , 2008, European journal of immunology.

[88]  Y. Toiyama,et al.  Decreased Expression of Monocyte Chemoattractant Protein-1 Predicts Poor Prognosis Following Curative Resection of Colorectal Cancer , 2008, Diseases of the colon and rectum.

[89]  P. Allavena,et al.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.

[90]  V. Beral,et al.  IARC MONOGRAPHS PROGRAMME ON THE EVALUATION OF CARelNOGENIC RISKS TO HUMANS' , 2008 .

[91]  J. Talmadge,et al.  Inflammatory cell infiltration of tumors: Jekyll or Hyde , 2007, Cancer and Metastasis Reviews.

[92]  W. Gong,et al.  CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. , 2007, Cancer letters.

[93]  A. Darzi,et al.  Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer , 2007, Clinical & Experimental Metastasis.

[94]  D. Galson,et al.  Monocyte chemotactic protein‐1 (MCP‐1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion , 2006, The Prostate.

[95]  H. Hammad,et al.  Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses , 2006, European Respiratory Journal.

[96]  Alessandro Antonelli,et al.  Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. , 2006, Cytokine.

[97]  Alberto Mantovani,et al.  Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.

[98]  D. Gabrilovich,et al.  Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer , 2006, Cancer Immunology, Immunotherapy.

[99]  C. Shriver,et al.  Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients , 2006, Clinical Cancer Research.

[100]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[101]  L. Hefler,et al.  Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer , 2004, Tumor Biology.

[102]  B. Rollins,et al.  CCL2 (monocyte chemoattractant protein-1) and cancer. , 2004, Seminars in cancer biology.

[103]  P. Allavena,et al.  The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. , 2003, Cancer research.

[104]  K. Chayama,et al.  Monocyte chemoattractant protein‐1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas , 2002, International journal of cancer.

[105]  H. Tonouchi,et al.  Profile of Monocyte Chemoattractant Protein-1 Circulating Levels in Gastric Cancer Patients , 2002, Scandinavian journal of gastroenterology.

[106]  H. Saji,et al.  Significant correlation of monocyte chemoattractant protein‐1 expression with neovascularization and progression of breast carcinoma , 2001, Cancer.

[107]  C. Franceschi,et al.  Chemokines, sTNF-Rs and sCD30 serum levels in healthy aged people and centenarians , 2001, Mechanisms of Ageing and Development.

[108]  H. Saji,et al.  Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[109]  Y. Ouchi,et al.  Increase in circulating levels of monocyte chemoattractant protein-1 with aging. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[110]  G. Heinze,et al.  Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients , 1999, British Journal of Cancer.

[111]  A. Zuckerman,et al.  IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1995, IARC monographs on the evaluation of carcinogenic risks to humans.

[112]  R. L. Carter,et al.  IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man , 1976 .

[113]  B. Terracini.  Evaluation of Carcinogenic Risk of Chemicals to Man , 1972 .

[114]  H. Vainio,et al.  Helsinki Criteria update 2014: asbestos continues to be a challenge for disease prevention and attribution. , 2016, Epidemiologia e prevenzione.

[115]  F. Tas,et al.  Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer , 2015, Cancer Chemotherapy and Pharmacology.

[116]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[117]  E. Corey,et al.  Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone , 2008, Clinical & Experimental Metastasis.

[118]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[119]  N. Jonjić,et al.  Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. , 1998, Pathology, research and practice.